Newsroom

April 2026

Biognosys Group Announces Collaboration with The Michael J. Fox Foundation to Advance Parkinson’s Disease Research Through the Development of Improved Biomarker Assays

Collaboration supports global LRRK2 Investigative Therapeutics Exchange (LITE) to accelerate development of reliable biomarkers for Parkinson’s disease

November 2025

Biognosys Launches New Plasma Proteomics Solution P2-iST and OmicsFlow Platform, and Announces the Formation of Biognosys Group

Biognosys has become part of the newly established Biognosys Group, an affiliate of Bruker. The Biognosys Group delivers high-performance, robust solutions across proteomics, met [...]

September 2025

Biognosys to Launch Metabolomics/Lipidomics Services for Multiomics Drug Discovery and Clinical Research

New biocrates metabolomics/lipidomics offering enhances Biognosys’ proteomics capabilities to support multiomic drug discovery and clinical/translational research

May 2025

Biognosys Launches Spectronaut 20 and SpectroMine 5, Setting New Benchmarks in Immunopeptidomics

Biognosys, a global leader in mass spectrometry-based proteomics solutions, announces the launch of Spectronaut® 20 and SpectroMine™ 5 at the ASMS 2025 Annual Conference, ta [...]

May 2025

SISCAPA and Biognosys Announce Strategic Collaboration to Deliver End-to-End High-Sensitivity Targeted Protein Quantification Solutions

Empowering biopharma with seamless, high-precision workflows from biomarker discovery to targeted enrichment and protein quantification for clinical trials 

January 2025

Biognosys in Publications 2024

We are proud to highlight the diverse range of applications supported by our proteomics software in 2024. Spectronaut has been instrumental in driving scientific discoveries across [...]

December 2024

IonOpticks’ Custom Chromatography Column to Become Biognosys’ Standard for High-Quality Proteomic Insights

October 2024

Biognosys Presents Major Innovations Across the Spectrum of Proteomics Research Applications at the HUPO World Congress

Biognosys’ proprietary P2 Plasma Enrichment System enables plasma proteome profiling with unprecedented depth and throughput, both as contract research and in-house via licensing [...]

September 2024

Biognosys Enters Reselling Agreement for Spectronaut Proteomics Software with Leading Provider of Mass Spectrometry Systems

Biognosys’ Spectronaut®, the leading vendor-agnostic software for DIA proteomics, is now directly available from Thermo Fisher Scientific under a reselling agreement.